PROCEPT BioRobotics delivered a strong second quarter in 2025, with total revenue reaching $79.2 million, a 48% increase year-over-year, driven by robust global demand and continued procedural momentum. The company also increased its fiscal year 2025 total revenue guidance.

The company saw strong revenue growth driven by U.S. handpiece sales and international expansion. While it remained unprofitable, it reduced its net loss and showed positive momentum with its Hydros™ system adoption among large health networks.

PROCEPT BioRobotics reported revenue of $68.2 million for Q4 2024, a 57% increase year-over-year. The company recorded a net loss of $18.9 million, improving from a loss of $27.5 million in the prior year period. Operating expenses increased due to commercial expansion and higher general and administrative costs. Gross margin improved to 64% from 49% in the prior year period.

PROCEPT BioRobotics reported a strong third quarter in 2024, with total revenue increasing by 66% compared to the prior year period. The company launched HYDROS, contributing to U.S. handpiece and consumables revenue growth of 74%. Gross margin reached a record 63.2%. The company increased its full year 2024 revenue and Adjusted EBITDA guidance.

PROCEPT BioRobotics reported a strong second quarter in 2024, with a 61% increase in total revenue compared to the prior year. The company also achieved record gross margins of 59% and demonstrated operating expense leverage. Increased revenue guidance for 2024 was provided.

PROCEPT BioRobotics reported a 72% increase in total revenue to $35.1 million for Q3 2023, driven by strong U.S. performance, particularly in handpiece and system sales. The company increased its full-year revenue guidance to $133.5 million and successfully completed an equity follow-on offering.

PROCEPT BioRobotics reported a strong second quarter with total revenue of $33.1 million, a 98% increase compared to the prior year period. U.S. revenue grew by 102% to $29.9 million, driven by system sales and increased handpiece revenue. The company increased its full-year 2023 revenue guidance to $131 million and achieved a gross margin of 56%.

PROCEPT BioRobotics reported a 72% increase in total revenue to $24.4 million for Q1 2023, with U.S. revenue up 73%. The company's U.S. handpiece and consumable revenue increased by 165%. They have increased their full year 2023 revenue guidance to $128.0 million.

PROCEPT BioRobotics reported a strong fourth quarter with a 135% increase in revenue compared to the prior year period. The company's U.S. system and consumable sales drove growth, and the installed base of AquaBeam Robotic Systems in the U.S. reached 167. The company issued 2023 total revenue guidance of approximately $125 million.

PROCEPT BioRobotics reported a strong third quarter with total revenue of $20.3 million, a 135% increase compared to the prior year period. The company increased its fiscal year 2022 total revenue guidance to approximately $72.5 million, representing 110% growth compared to 2021.

PROCEPT BioRobotics reported a strong first quarter in 2022, with total revenue increasing by 97% compared to the prior year period. The growth was primarily driven by U.S. revenues, including system sales and handpiece revenue. The company also increased its full year 2022 total revenue guidance range to $58.0 million to $62.0 million.

PROCEPT BioRobotics reported Q4 2021 revenue of $10.1 million, a significant increase from $3.2 million in the same period of 2020. The growth was primarily driven by system sales to new hospital customers and increased utilization among existing customers. The company's gross margin also improved substantially, reaching 44.5% compared to 14.6% in the prior year period.

PROCEPT BioRobotics reported strong third-quarter results, with total revenue reaching $8.7 million, a significant increase from $2.1 million in the prior year period. The company's U.S. system revenue was $5.0 million, compared to $0.6 million in the prior year period. The company issued 2021 total revenue guidance range of $33.0 to $33.3 million.